Myles Hume

Investors take note of Opthea’s potential

Australian biotech company Opthea has reported a solid cash position to further advance clinical trials of its lead drug candidate OPT-302 in FY20, as it moves closer to imposing itself on the macular disease market. Read more

© All Rights Reserved. All content published on this site is the property of Prime Creative Media. Unauthorised reproduction is prohibited

JOIN OUR NEWSLETTER

JOIN OUR NEWSLETTER
Close